Role of Epicardial Adipose Tissue in Coronary Artery Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by McMaster University.
Recruitment status was  Recruiting
Heart and Stroke Foundation of Canada
Information provided by:
McMaster University Identifier:
First received: January 17, 2006
Last updated: August 9, 2006
Last verified: January 2006
We sight to evaluate whether patients with coronary artery disease (CAD) have more epicardial fat than patients without CAD, which would suggest that epicardial fat may be more than an “innocent bystander” and be actively involved in the disease process. Its role as a modulator of vascular response and myocardial function could potentially lead to new areas of cardiac research. We also sight to evaluate whether epicardial fat from patients with CAD releases more adipokines than subcutaneous fat from these patients which could prompt studies into the differential regulation of adipokine secretion in this tissue. Thus for e.g., the use of thiazolidinediones (glitazones), statins, ARBs or other compounds that can specifically modulate adipokine secretion could be explored to determine their benefit in ameliorating the effects attributable to increased epicardial fat.

Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Cross-Sectional
Official Title: Role of Epicardial Adipose Tissue in Coronary Artery Disease

Resource links provided by NLM:

Further study details as provided by McMaster University:

Estimated Enrollment: 50
Study Start Date: January 2006
Estimated Study Completion Date: December 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients elegible for elective cardiac surgery are elegible
  • Ability to provide written informed consent in accordance with GCP guidelines and local legislations.
  • > 18 years of age

Exclusion Criteria:

  • Control patients will not have clinical signs of CAD and will show normal coronary arteries on angiography.
  • Any medical, social or geographic condition, which, in the opinion of the investigator would not allow safe or reliable completion of the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00279227

Contact: Suzana Damjanovic, MLT, CCRA 905-527-4322 ext 44710

Canada, Ontario
Hamilton Health Sciences - Cardiovascular Obesity Research and Management Center Recruiting
Hamilton, Ontario, Canada, L8L 2X2
Sub-Investigator: Gianluca Iacobellis, MD PhD         
Principal Investigator: Arya M Sharma, MD FRCPC         
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Heart and Stroke Foundation of Canada
Principal Investigator: Arya M Sharma, MD, FRCPC McMaster University
  More Information

No publications provided Identifier: NCT00279227     History of Changes
Other Study ID Numbers: EPICARD Study
Study First Received: January 17, 2006
Last Updated: August 9, 2006
Health Authority: Canada: Health Canada

Keywords provided by McMaster University:
coronary artery disease
epicardial adipose tissue
epicardial fat

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases processed this record on November 27, 2015